Coya Therapeutics, Inc. Announces \$30 Million At-the-Market Equity Offering Agreement with Leerink Partners LLC
Key Points from the 8-K Filing
- Sales Agreement Signed: On May 12, 2026, Coya Therapeutics, Inc. (“Coya” or “the Company”) entered into a Sales Agreement with Leerink Partners LLC, allowing the Company to offer and sell shares of its common stock for aggregate gross proceeds of up to \$30,000,000.
- At-the-Market (ATM) Offering: Shares may be offered and sold from time to time through or to Leerink Partners as the sales agent. Sales will be made via an at-the-market offering under a shelf registration statement on Form S-3 (File No. 333-289511).
- Commission Structure: Leerink Partners will receive a commission of 3.0% of the aggregate gross proceeds from the shares sold.
- Use of Proceeds: The net proceeds from this offering will be used as described in the prospectus supplement under “Use of Proceeds.” (Details on the specific intended uses were not included in this filing and should be referenced in the prospectus supplement.)
- Customary Terms: The Sales Agreement contains standard representations, warranties, indemnification, and closing conditions customary for such transactions.
- Emerging Growth Company: Coya is classified as an “emerging growth company” under the Securities Act.
- Listing and Compliance: Coya’s common stock is listed on Nasdaq under the ticker symbol COYA. The company is in compliance with Nasdaq listing standards and has filed a Notification of Listing of Additional Shares with Nasdaq for the Placement Shares.
- Legal Opinion: The filing includes a legal opinion from Lowenstein Sandler LLP, confirming that the shares to be issued will be validly issued, fully paid, and non-assessable under Delaware law.
- No Other Agreements: The company is not party to any other “at the market” or continuous equity transaction agreements.
Important Information for Shareholders
- Potential Share Dilution: The issuance of up to \$30 million in new common shares may result in dilution for existing shareholders. This could impact the stock price depending on the volume and timing of sales under the ATM program.
- Market Sensitivity: ATM offerings can add supply to the market, potentially exerting downward pressure on the share price, especially if executed during periods of low trading volume or adverse market conditions.
- No Immediate Sale: No shares will be offered or sold in any jurisdiction where such offer or sale would be unlawful without proper registration or qualification under local securities laws.
- Conditional Sales: Leerink Partners’ obligations to sell shares are subject to standard closing conditions and the company’s ongoing compliance with its contractual representations and warranties.
- No Material Adverse Change: The agreement includes representations that there has been no material adverse change in the company’s financial condition or business since the last reporting period.
- Transparency and Reporting: The company is required to maintain compliance with all filing and disclosure obligations under the Securities Exchange Act of 1934, including prompt amendments or supplements to correct any material misstatements or omissions in its filings or prospectus.
- No Unusual Relationships: There are no undisclosed related party transactions or other relationships required to be disclosed under SEC rules.
Potential Market Impact
The announcement of an at-the-market equity offering of up to \$30 million is potentially price sensitive and may impact Coya Therapeutics’ share price. Investors should be aware of the risk of dilution and possible increased volatility as shares are sold into the market. The company’s ability to raise capital efficiently and the manner in which it utilizes the proceeds will be closely monitored by the market. Successful execution of this offering may strengthen the company’s balance sheet and fund growth initiatives, but aggressive share issuance could weigh on the stock if not paired with positive business developments.
Shareholders and prospective investors are encouraged to review the prospectus supplement and additional filings for more detailed information regarding the use of proceeds, risk factors, and the company’s current financial position.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The information provided is based on publicly available filings as of the date of this article and may be subject to change without notice.
